FDA Accepts Filament Health’s IND Application For Addiction Drug Candidate   

The FDA accepted Filament Health’s Investigational New Drug application for PEX010, its botanical psilocybin drug candidate, for the treatment of substance use disorder (SUD). The company has also previously submitted the IND-opening protocol for PEX010 to Health Canada.;;

According to FIlament Health, 24 research institutions and licensing partners in Canada, the U.S., Europe, and Israel are studying PEX010 for conditions including alcohol use disorder, depression, and coma.;

Filament Health, which was founded in Canada in 2020, is a clinical-stage natural psychedelic drug development company.;;;

This was reported by Filament Health . . .